IP Library Granted Patent US 8,252,740
Granted Patent B2
US 8,252,740 · App. 12/162,283 · Granted Aug 28, 2012

Thermally-targeted delivery of medicaments including doxorubicin

Assignee: The University of Mississippi Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,740
App. No.
12/162,283
Granted
Aug 28, 2012
Kind
B2
Abstract

Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat peptide, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) (SEQ ID NO: 3) spacer and a cysteine residue (SEQ ID NO: 4) conjugated to therapeutic such as doxorubicin, or an analog thereof.

Claims (14)

1. A composition, comprising an ELP-containing protein, a GFLG (SEQ ID NO: 3) linker coupled thereto, and a therapeutic agent coupled with the linker, wherein the GFLG (SEQ ID NO: 3) linker comprises a C-terminal cysteine residue coupled to the therapeutic agent.

2. The composition of claim 1 , wherein ELP is a five amino acid repeat comprising the sequence XGVPG (SEQ ID NO: 1), wherein X is any amino acid except proline.

3. The composition of claim 1 , wherein the therapeutic agent is a chemotherapeutic agent.

4. The composition of claim 3 , wherein the chemotherapeutic agent is doxorubicin.

5. The composition of claim 3 , wherein the chemotherapeutic agent is methotrexate, vinblastin, or paclitaxel.

6. The composition of claim 1 , comprising a cell-penetrating peptide sequence coupled with the ELP.

7. The composition of claim 6 , wherein the cell-penetrating peptide sequence is a Tat peptide.

8. The composition of claim 6 , wherein the cell-penetrating peptide is selected from Antp, Tat, MTS, Bac-7, Trans, and pVEC.

9. The composition of claim 1 , which is Tat-ELP-GFLGC (SEQ ID NO: 4)—therapeutic agent.

10. The composition of claim 9 , wherein the therapeutic agent is Dox.

11. The composition of claim 1 , with a phase transition of about 39° C. to about 42° C.

12. A method of delivering a therapeutic agent to a tumor, comprising the steps of: administering a composition of claim 1 ; and applying local hyperthermia to the tumor site.

13. A method of treating, preventing, or managing cancer, comprising: administering a composition of claim 1 ; and applying local hyperthermia to a tumor site.

14. The method of claim 12 or claim 13 , wherein the tumor is a breast tumor, lung tumor, colon cancer, or melanoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2008
From: RAUCHER, DRAZEN; BIDWELL, GENE, III; PRIEBE, WALDEMAR; FOKT, IZABELA
To: THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
Reel/Frame 021295/0617 →
Continuity (2)
Provisional Application 60762919 · Jan 27, 2006
Related Publication 20100022466A1 · Jan 28, 2010